Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Birch, Ashley H ^a   Arcand, Suzanna L ^b   Oros, Kathleen K ^c   Rahimi, Kurosh ^d   Watters, A Kevin ^e   Provencher, Diane ^d,f   Greenwood, Celia M ^a,c   Mes Masson, Anne Marie ^d,f   Tonin, Patricia N ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BENIGN TUMOR; BRAF GENE; CANCER CLASSIFICATION; CANCER GRADING; CARCINOGENESIS; CHROMOSOME 12P; CHROMOSOME 3P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FUSION GENE; GAIN OF FUNCTION MUTATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOME ANALYSIS; GOPC ROS1 FUSION GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KRAS GENE; LOW GRADE OVARIAN SEROUS TUMOR; LOW MALIGNANT POTENTIAL TUMOR; NEOPLASM; NONHUMAN; ONCOGENE; OVARY TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TP53 GENE; TUMOR SUPPRESSOR GENE; CHROMOSOME 3; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; GENOTYPE; HOMOZYGOTE; METABOLISM; METASTASIS; MUTATION; ONCOGENE RAS; OVARY; PATHOLOGY;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; GENOTYPE; HOMOZYGOTE; HUMANS; MUTATION; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; OVARY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 82755170504     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028250     Document Type: Article

References (78)

1. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, et al. (2003) Pathology and classification of ovarian tumors. Cancer 97: 2631-2642.
2. Trimble CL, Kosary C, Trimble EL, (2002) Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 86: 34-37.
3. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, et al. (2002) Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 99: 3-10.
4. Vang R, Shih Ie M, Kurman RJ, (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16: 267-282.
5. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, et al. (2008) Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108: 510-514.
6. Li AJ, Karlan BY, (2001) Genetic factors in ovarian carcinoma. Curr Oncol Rep 3: 27-32.
7. Helou K, Padilla-Nash H, Wangsa D, Karlsson E, Osterberg L, et al. (2006) Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 170: 1-8.
8. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, et al. (1995) Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 55: 6172-6180.
9. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, et al. (2001) Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 91: 534-540.
10. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, et al. (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69: 4036-4042.
11. Staebler A, Heselmeyer-Haddad K, Bell K, Riopel M, Perlman E, et al. (2002) Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Hum Pathol 33: 47-59.
12. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, et al. (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29: 218-224.
13. Schuyer M, Henzen-Logmans SC, van der Burg ME, Fieret JH, Derksen C, et al. (1999) Genetic alterations in ovarian borderline tumours and ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol 82: 147-150.
14. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95: 484-486.
15. de Nictolis M, Montironi R, Tommasoni S, Carinelli S, Ojeda B, et al. (1992) Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 70: 152-160.
16. Bernardini M, Weberpals J, Squire JA, (2004) The use of cytogenetics in understanding ovarian cancer. Biomed Pharmacother 58: 17-23.
17. Mertens F, Johansson B, Hoglund M, Mitelman F, (1997) Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res 57: 2765-2780.
18. Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, et al. (1999) Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 59: 4662-4667.
19. Lounis H, Mes-Masson AM, Dion F, Bradley WE, Seymour RJ, et al. (1998) Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene 17: 2359-2365.
20. Zhang GL, Xu KL, (2002) Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China. Int J Gynecol Cancer 12: 198-201.
21. Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN, (2002) Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog 34: 78-90.
22. Cody NA, Ouellet V, Manderson EN, Quinn MC, Filali-Mouhim A, et al. (2007) Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 26: 618-632.
23. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, et al. (2009) Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog 48: 1077-1092.
24. Manderson EN, Birch AH, Shen Z, Mes-Masson AM, Provencher D, et al. (2009) Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. Int J Gynecol Cancer 19: 513-525.
25. Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, et al. (2008) Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog 47: 56-65.
26. Gorringe KL, Campbell IG, (2009) Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 3: 157-164.
27. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, et al. (2007) High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 13: 4731-4739.
28. Hauptmann S, Denkert C, Koch I, Petersen S, Schluns K, et al. (2002) Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 33: 632-641.
29. Hu J, Khanna V, Jones MM, Surti U, (2002) Genomic imbalances in ovarian borderline serous and mucinous tumors. Cancer Genet Cytogenet 139: 18-23.
30. Osterberg L, Akeson M, Levan K, Partheen K, Zetterqvist BM, et al. (2006) Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet 167: 103-108.
31. Wolf NG, Abdul-Karim FW, Farver C, Schrock E, du Manoir S, et al. (1999) Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25: 307-315.
32. Pejovic T, Heim S, Mandahl N, Elmfors B, Furgyik S, et al. (1991) Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 47: 358-361.
33. McQuillan R, Leutenegger AL, Abdel-Rahman R, Franklin CS, Pericic M, et al. (2008) Runs of homozygosity in European populations. Am J Hum Genet 83: 359-372.
34. Simon-Sanchez J, Scholz S, Fung HC, Matarin M, Hernandez D, et al. (2007) Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet 16: 1-14.
35. Imura M, Yamashita S, Cai LY, Furuta J, Wakabayashi M, et al. (2006) Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines. Cancer Lett 241: 213-220.
36. Katsaros D, Cho W, Singal R, Fracchioli S, Rigault De La Longrais IA, et al. (2004) Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94: 685-692.
37. Murphy MA, Wentzensen N, (2010) Frequency of mismatch repair deficiency in ovarian cancer: A systematic review. Int J Cancer 2010 Dec 7 [Epub ahead of print].
38. Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, et al. (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55: 2150-2157.
39. Charest A, Lane K, McMahon K, Park J, Preisinger E, et al. (2003) Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37: 58-71.
40. Gu TL, Deng X, Huang F, Tucker M, Crosby K, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6: e15640.
41. McCluskey LL, Chen C, Delgadillo E, Felix JC, Muderspach LI, et al. (1999) Differences in p16 gene methylation and expression in benign and malignant ovarian tumors. Gynecol Oncol 72: 87-92.
42. Choi YL, Kang SY, Shin YK, Choi JS, Kim SH, et al. (2006) Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 448: 331-336.
43. Roy WJ Jr, Watson RH, Hitchcock A, Campbell IG, (1997) Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours. Oncogene 15: 2031-2035.
44. Thomas NA, Neville PJ, Baxter SW, Campbell IG, (2003) Genetic analysis of benign ovarian tumors. Int J Cancer 105: 499-505.
45. Assie G, LaFramboise T, Platzer P, Bertherat J, Stratakis CA, et al. (2008) SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet 82: 903-915.
46. Angeloni D, ter Elst A, Wei MH, van der Veen AY, Braga EA, et al. (2006) Analysis of a new homozygous deletion in the tumor suppressor region at 3p12.3 reveals two novel intronic noncoding RNA genes. Genes Chromosomes Cancer 45: 676-691.
47. Gibson J, Morton NE, Collins A, (2006) Extended tracts of homozygosity in outbred human populations. Hum Mol Genet 15: 789-795.
48. Wang S, Haynes C, Barany F, Ott J, (2009) Genome-wide autozygosity mapping in human populations. Genet Epidemiol 33: 172-180.
49. Roy-Gagnon MH, Moreau C, Bherer C, St-Onge P, Sinnett D, et al. (2011) Genomic and genealogical investigation of the French Canadian founder population structure. Hum Genet 129: 521-31.
50. Lencz T, Lambert C, DeRosse P, Burdick KE, Morgan TV, et al. (2007) Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A 104: 19942-19947.
51. Ku CS, Naidoo N, Teo SM, Pawitan Y, (2011) Regions of homozygosity and their impact on complex diseases and traits. Hum Genet 129: 1-15.
52. Pejovic T, Iosif CS, Mitelman F, Heim S, (1996) Karyotypic characteristics of borderline malignant tumors of the ovary: trisomy 12, trisomy 7, and r(1) as nonrandom features. Cancer Genet Cytogenet 92: 95-98.
53. Yang-Feng TL, Li SB, Leung WY, Carcangiu ML, Schwartz PE, (1991) Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J Cancer 48: 678-681.
54. Modrek B, Ge L, Pandita A, Lin E, Mohan S, et al. (2009) Oncogenic activating mutations are associated with local copy gain. Mol Cancer Res 7: 1244-1252.
55. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, et al. (2011) Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol 6: 15-20.
56. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, et al. (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
57. Negrini S, Gorgoulis VG, Halazonetis TD, (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228.
58. Landen CN Jr, Birrer MJ, Sood AK, (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005.
59. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, et al. (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65: 10602-10612.
60. Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, et al. (2005) Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 24: 4672-4687.
61. Henrichsen CN, Chaignat E, Reymond A, (2009) Copy number variants, diseases and gene expression. Hum Mol Genet 18: R1-8.
62. Charest A, Kheifets V, Park J, Lane K, McMahon K, et al. (2003) Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A 100: 916-921.
63. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, et al. (2006) ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 66: 7473-7481.
64. Shepherd R, Forbes SA, Beare D, Bamford S, Cole CG, et al. (2011) Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) 2011: bar018.
65. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
66. Ouellet V, Zietarska M, Portelance L, Lafontaine J, Madore J, et al. (2008) Characterization of three new serous epithelial ovarian cancer cell lines. BMC Cancer 8: 152.
67. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, et al. (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36: 357-361.
68. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, et al. (1994) Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 215: 303-309.
69. Tang W, David FB, Wilson MM, Barwick BG, Leyland-Jones BR, et al. (2009) DNA extraction from formalin-fixed, paraffin-embedded tissue. Cold Spring Harb Protoc 2009: pdb prot5138.
70. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, et al. (2003) Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 22: 1568-1579.
71. Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, et al. (2010) The UCSC Genome Browser database: update 2010. Nucleic Acids Res 38: D613-619.
72. Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, et al. (2008) Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat 108: 399-408.
73. Clark SJ, Harrison J, Paul CL, Frommer M, (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997.
74. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, et al. (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699.
75. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB, (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93: 9821-9826.
76. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95: 6870-6875.
77. Sun W, Wright FA, Tang Z, Nordgard SH, Van Loo P, et al. (2009) Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res 37: 5365-5377.
78. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, et al. (2005) Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 43: 141-154.